H.C. Wainwright analyst Robert Burns raised the firm’s price target on Revolution Medicines (RVMD) to $73 from $72 and keeps a Buy rating on ...

In a historical move, the nation’s top court has agreed to hear an appeal by socially poor Dalit Catholics in southern India ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Revolution Medicines (RVMD – Research Report) and Genmab ...